Patienter med kronisk hepatitis B eller C behandlet med antiviral kombinationsbehandling har øget risiko for alvorlige og potentielt fatale leverpåvirkninger.
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse events.